Get started
Author

Zexin Ren

Observed institution: George Washington University
ORCID: 0009-0000-9544-6328
Observed ORCID: 0009-0000-9544-6328
OpenAlex ID: A5111336727
Explanation-based Adversarial Detection with Noise Reduction
2024 · Juntao Su, Zhou Yang, et al. · IEEE International Conference on Big Data (BigData) · 3
Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al. · Cancer Research Communications · 1
Leveraging AI for validating the association between minimal residual disease (MRD) and survival outcomes in multiple myeloma.
2025 · Zexin Ren, Zixuan Zhao, et al. · Journal of Clinical Oncology · 1
AI-Generated Synthetic Patient Data Helps in Evaluating Daratumumab Treatment Benefit in Multiple Myeloma Subgroups
2024 · Merav Bar, Andrew J. Cowan, et al. · Blood · 1
PDF
Figure S8 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure S4 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure S12 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure S6 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Table 3 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure S5 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Table 2 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure S9 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Data from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure S1 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure S2 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure S7 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure 1 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure S3 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Table 1 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure S10 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Descriptive notes for supplement from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Table 4 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Figure S11 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
2026 · Zexin Ren, Zixuan Zhao, et al.
Evaluation of daratumumab for treating multiple myeloma in patients with high-risk cytogenetic factors: A pooled analysis using synthetic individual patient data.
2025 · Zixuan Zhao, Zexin Ren, et al. · Journal of Clinical Oncology
PDF
P-178 Leveraging AI for Modeling MRD and Survival Outcomes in Multiple Myeloma Based on Comprehensive and Up-to-Date Clinical Evidence
2024 · Zexin Ren, Zixuan Zhao, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 25
Citation count: 6
H-index: 1
I10-index:
Year
Topic
Type